Agonist – Page 2

Denali Therapeutics’ ALS Drug DNL343 Fails to Meet Primary Efficacy Endpoints in Phase 2/3 HEALEY ALS Platform Trial

6 months ago talkbio0Tagged Agonist, Amyotrophic Lateral Sclerosis, Clinical trial failure, Denali, DNL343, Eukaryotic Initiation Factor-2B, HEALEY, Neurodegenerative Disorders

Denali Therapeutics, DNL343, ALS (Amyotrophic Lateral Sclerosis), HEALEY ALS Platform Trial, eIF2B agonist, Clinical trial failure, Neurodegenerative diseases

GUBamy, a Weekly Amylin Agonist, Shows Promising Weight Loss and Tolerability in Phase 1 Trial

8 months ago talkbio0Tagged Agonist, Amylin, GUBamy, long-acting, Obesity, phase 1 trial, Weight Loss

Amylin agonist, Obesity treatment, Weight loss, Phase 1 trial, GUBamy, Long-acting amylin agonist

Novo Nordisk Secures $285 Million Biobucks Deal with Ascendis Pharma for Monthly GLP-1 Agonist Development

8 months ago talkbio0Tagged Agonist, Ascendis, biobucks, Drug Development, Glucagon-Like Peptide 1, Nordisk, Pharma

Novo Nordisk, Ascendis Pharma, GLP-1 agonist, biobucks deal, pharmaceutical development

Novo Nordisk Reports Significant Weight Loss with New Dual-Acting Oral Drug in Early Clinical Trial

10 months ago talkbio0Tagged Agonist, Clinical Trials, dual-acting oral drug, Glucagon-Like Peptide-1 Receptor, Nordisk, Obesity

Novo Nordisk, weight loss, dual-acting oral drug, early clinical trial, obesity treatment, GLP-1 receptor agonist

Centessa’s ORX750 Demonstrates Promising ‘Best-in-Class’ Profile in Early Narcolepsy Trial

10 months ago talkbio0Tagged Agonist, Centessa Pharmaceuticals, Clinical Trials, Narcolepsy, ORX750, Phase 1 (qualifier value), sleep-wake disorders

Centessa Pharmaceuticals, ORX750, narcolepsy, orexin receptor 2 agonist, sleep-wake disorders, clinical trial, Phase 1 data

Terns Pharmaceuticals’ Oral GLP-1R Agonist TERN-601 Shows Promising Weight Loss in Phase 1 Trial

10 months ago talkbio0Tagged Agonist, Laridae, Obesity, Oral cavity, phase 1 trial, TERN-601, Weight Loss

Terns Pharmaceuticals, TERN-601, Oral GLP-1R Agonist, Phase 1 Trial, Weight Loss, Obesity Treatment

ImmunityBio Secures FDA Approval for ANKTIVA but Faces Financial Challenges

10 months ago talkbio0Tagged Agonist, Anktiva, Approved, Cancer Therapeutic Procedure, financial troubles, ImmunityBio, Immunotherapy, Interleukin-15, United States Food and Drug Administration

ImmunityBio, FDA approval, ANKTIVA, financial troubles, cancer treatment, IL-15 agonist immunotherapy

Syros Discontinues Mid-Stage Tamibarotene Program in Frontline Acute Myeloid Leukemia (AML)

11 months ago talkbio0Tagged Agonist, azacitidine, Clinical Trials, Futility Analysis, Leukemia, Myelocytic, Acute, RARα, SELECT-AML-1, Syros Pharmaceuticals, tamibarotene, venetoclax

Syros Pharmaceuticals, Tamibarotene, Acute Myeloid Leukemia (AML), Clinical Trial, SELECT-AML-1, Venetoclax, Azacitidine, RARα Agonist, Futility Analysis